CLINICAL_TRIALS
trial_result
· 2016-07-11
Clinical Trial Update: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial [Phase 2]
Summary
Phase II clinical trial update for novel therapies targeting resistant focal segmental glomerulosclerosis (FSGS) under FONTII, with results posted after study c…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: NYU Langone Health | Conditions: Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-07-11